# Efficacy of Cardioviva™ Probiotic Supplement Capsule Formulation

Study · id `cardio:ct-nct01341613` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01341613](<https://clinicaltrials.gov/study/NCT01341613>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01341613

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 131 participants.

## Technical summary

Registry record NCT01341613. Randomized; quadruple masking; primary purpose treatment. Start 2011-05 (registry gives no type); primary completion 2011-10 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 131 participants (enrolled count; ClinicalTrials.gov record NCT01341613, source copy `cardio:ctgov-nct01341613-2011-11-02`, retrieved 2026-10-31)
- Start date: 2011-05 (registry gives no type) (ClinicalTrials.gov record NCT01341613, source copy `cardio:ctgov-nct01341613-2011-11-02`, retrieved 2026-10-31)
- Primary completion: 2011-10 (actual) (ClinicalTrials.gov record NCT01341613, source copy `cardio:ctgov-nct01341613-2011-11-02`, retrieved 2026-10-31)
- Completion: 2011-10 (actual) (ClinicalTrials.gov record NCT01341613, source copy `cardio:ctgov-nct01341613-2011-11-02`, retrieved 2026-10-31)
- Countries: Czechia (ClinicalTrials.gov record NCT01341613, source copy `cardio:ctgov-nct01341613-2011-11-02`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01341613-2011-11-02`, retrieved 2026-10-31)

## The registry's words

- Brief title: Efficacy of Cardioviva™ Probiotic Supplement Capsule Formulation
- Condition: Hypercholesterolemia
- Intervention (Dietary supplement): Cardioviva™ supplement capsule
- Intervention (Dietary supplement): Placebo capsule
- Lead sponsor: Micropharma Limited
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Evaluation of clinical safety and tolerance of a Lactobacillus reuteri NCIMB 30242 supplement capsule: a randomized control trial (`cardio:pubmed-22561556`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Improvement of gastrointestinal health status in subjects consuming Lactobacillus reuteri NCIMB 30242 capsules: a post-hoc analysis of a randomized controlled trial (`cardio:pubmed-24074303`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 29d3ed5fe528f7957d5a4d6ff0d6ddb5079436c6b92d4b202ea88da2dc7b8c2f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
